Metabolomics Reveals Amino Acids Contribute to Variation in Response to Simvastatin Treatment

Miles Trupp1✉, Hongjie Zhu2✉, William R. Wikoff3*, Rebecca A. Baillie4✉, Zhao-Bang Zeng5, Peter D. Karp1, Oliver Fiehn3, Ronald M. Krauss6✉, Rima Kaddurah-Daouk2✉

1 Bioinformatics Research Group, AI Center, SRI International, Menlo Park, California, United States of America, 2 Duke University Medical Center, Durham, North Carolina, United States of America, 3 Genomics Center, University of California, Davis, California, United States of America, 4 Rosa and Company, Cupertino, California, United States of America, 5 Bioinformatics Research Center, NC State University, Raleigh, North Carolina, United States of America, 6 Children’s Hospital Oakland Research Institute, Oakland, California, United States of America

Abstract

Statins are widely prescribed for reducing LDL-cholesterol (C) and risk for cardiovascular disease (CVD), but there is considerable variation in therapeutic response. We used a gas chromatography-time-of-flight mass-spectrometry-based metabolomics platform to evaluate global effects of simvastatin on intermediary metabolism. Analyses were conducted in 148 participants in the Cholesterol and Pharmacogenetics study who were profiled pre and six weeks post treatment with 40 mg/day simvastatin: 100 randomly selected from the full range of the LDL-C response distribution and 24 each from the top and bottom 10% of this distribution (“good” and “poor” responders, respectively). The metabolic signature of drug exposure in the full range of responders included essential amino acids, lauric acid (p<0.0055, q<0.055), and alphatocopherol (p<0.0003, q<0.017). Using the HumanCyc database and pathway enrichment analysis, we observed that the metabolites of drug exposure were enriched for the pathway class amino acid degradation (p<0.0032). Metabolites whose change correlated with LDL-C lowering response to simvastatin in the full range responders included cystine, urea cycle intermediates, and the dibasic amino acids ornithine, citrulline and lysine. These dibasic amino acids share plasma membrane transporters with arginine, the rate-limiting substrate for nitric oxide synthase (NOS), a critical mediator of cardiovascular health. Baseline metabolic profiles of the good and poor responders were analyzed by orthogonal partial least square discriminant analysis so as to determine the metabolites that best separated the two response groups and could be predictive of LDL-C response. Among these were xanthine, 2-hydroxyvaleric acid, succinic acid, stearic acid, and fructose. Together, the findings from this study indicate that clusters of metabolites involved in multiple pathways not directly connected with cholesterol metabolism may play a role in modulating the response to simvastatin treatment.

Trial Registration: ClinicalTrials.gov NCT00451828

Copyright: © 2012 Trupp et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Statins are HMG-CoA reductase inhibitors that are used to reduce LDL-cholesterol (LDL-C) and, thereby, to reduce CVD risk [1]. However, this class of drugs exhibits a broad spectrum of biological effects that may impact on CVD risk, including improvement of endothelial function by upregulation of endothelial NO synthase (eNOS), decrease in proliferation of vascular smooth muscle cells and macrophages, reduction of platelet activity, stabilization of atherosclerotic plaques, and antioxidant, anti-inflammatory and immunomodulatory effects [2]. In addition several clinically significant side effects have been documented, including myopathy and increased risk for developing Type II diabetes mellitus [3].

Multiple intervention trials with statin drugs have demonstrated a reduction in relative risk for both CVD and stroke. Nevertheless, residual CVD risk remains high and LDL-C response varies greatly. Variation in response to statins can be affected by genetic and environmental influences. Several genetic polymorphisms that contribute to variability in the LDL-C response to statins have
been identified [4], but only a small proportion of the variance has been explained by these factors. Additional variables affecting response to statins include diet [5], level of immune response [6], environmental conditions, and drug interactions [7]. Simvastatin is administered as an inactive precursor drug that is activated by endogenous biotransformation pathways. There is increasing interest in the role of gut bacteria in the metabolism of drugs [9], and recent data suggest that secondary bile acids produced by gut microbiome contribute to variation of LDL lowering response to simvastatin [9].

Inter-individual variation in response to statins, and the fact that LDL cholesterol and other biomarkers are not sufficient to predict clinical benefit or side effects, suggest that more reliable biomarkers are needed for identifying the sub-populations that may achieve the most benefit from statin use and those that might be at risk for developing side effects. Metabolomics provides powerful tools for mapping pathways implicated in disease and in response to drug treatment [10,11]. Sophisticated metabolic analytical platforms and informatics tools have been developed that have made it possible to define initial signatures for several diseases [12,13,14,15,16,17]. Metabolomic “signatures” present in patients who do and do not respond to drug therapy, i.e., signatures that reflect the drug response phenotype, could lead to mechanistic hypotheses that would provide insight into the underlying basis for individual variation in response to drugs such as antidepressants and statins [18,19,20].

Previously, using a targeted lipidomics platform, we found that baseline cholesterol ester and phospholipid metabolites were correlated with LDL-C response to treatment in individuals selected from the upper and lower tails of the LDL-C response distribution in the Cholesterol and Pharmacogenetics (CAP) study [21]. C-reactive protein (CRP) response to therapy correlated with baseline plasmalogens, lipids that are involved in inflammation, indicating that distinct metabolic changes are correlated with LDL-C and CRP response to statins. Using a second targeted metabolomics platform in participants from this study, secondary bile acids produced by the gut microbiome were found to be implicated in response to simvastatin [9].

In the present study, we used a non-targeted, broad spectrum pathway agnostic GC-TOF mass spectrometry platform to measure 160 metabolites in 148 CAP study participants and considered the following questions:

1. What is the metabolic signature of exposure to simvastatin?
2. Which elements of the drug signature correlate with LDL-C response?
3. What metabolites at baseline define distinct metabolic profiles (metabotypes) that can distinguish between good and poor response to simvastatin?

Results

Analyses in Individuals Sampled From the Full Range of LDL-C Response to Simvastatin

Metabolic signature of exposure to simvastatin. An untargeted, broad range GC-TOF metabolomics platform was used to profile plasma from 100 participants from across the full range of the distribution of LDL-C response in the CAP study (Table S1). Samples were analyzed before and after six weeks treatment with simvastatin 40 mg/d and Wilcoxon signed rank test was used to define metabolites that significantly changed during treatment (Table 1). Correlations among these metabolites are shown in Figure 1.

| Compound                  | Direction of Change | p-value | q-value |
|---------------------------|---------------------|---------|---------|
| $\alpha$-tocopherol       | decrease            | 0.0003  | 0.017   |
| cholesterol               | decrease            | 0.0027  | 0.055   |
| glycerol                  | increase            | 0.0035  | 0.055   |
| 2-hydroxyvaleric acid     | decrease            | 0.0039  | 0.055   |
| lactic acid               | decrease            | 0.0055  | 0.055   |
| threonine                 | increase            | 0.0060  | 0.055   |
| oxalic acid               | decrease            | 0.0090  | 0.069   |
| alanine                   | increase            | 0.0100  | 0.069   |
| phenylalanine             | increase            | 0.0110  | 0.069   |
| proline                   | increase            | 0.0180  | 0.1      |
| uridine                   | decrease            | 0.0200  | 0.1      |
| 2-ketoisocaproic acid     | increase            | 0.0270  | 0.12     |
| palmitoleic acid          | increase            | 0.0290  | 0.12     |
| epsilon-caprolactam       | increase            | 0.0300  | 0.12     |
| hydroxyxycarbamate$^H$    | decrease            | 0.0350  | 0.13     |
| $\gamma$-tocopherol       | decrease            | 0.0370  | 0.13     |
| 2-aminoacipic acid        | increase            | 0.0390  | 0.13     |
| beta-alanine              | decrease            | 0.0440  | 0.13     |
| creatinine                | increase            | 0.0450  | 0.13     |

Following simvastatin treatment, a significant decrease was found in plasma levels of cholesterol ($p<0.0027$, $q<0.005$), alpha-tocopherol ($p<0.0003$, $q<0.017$), and gamma-tocopherol ($p<0.037$, $q<0.13$) (vitamin E), and lactic acid ($p<0.0055$, $q<0.055$) (Table 1). Changes in levels of these three metabolites were significantly correlated with each other in samples from individuals across the full range of simvastatin response (Figure 1). Changes in cholesterol and lactic acid levels were positively correlated with changes in levels of 2-hydroxyvaleric acid ($p<0.0039$, $q<0.055$) (Figure 1). Plasma levels of threonine ($p<0.0060$, $q<0.055$), alanine ($p<0.010$, $q<0.069$), and phenylalanine ($p<0.011$, $q<0.069$), were increased following simvastatin treatment (Table 1). These increases in amino acids were all correlated with reduction in free cholesterol (Figure 1), and were all highly correlated with each other. A pattern of higher levels of essential amino acids appears when considering that 2-ketoisocaproic acid ($p<0.027$, $q<0.12$) and 2-aminoacipic acid ($p<0.039$, $q<0.13$), intermediates in the degradation of leucine and lysine respectively, were both increased by simvastatin treatment (Table 1). Using the HumanCyc database and the pathway enrichment analysis component of Pathway Tools software, we observed that the metabolites in Table 1 were enriched for the pathway class amino acid degradation with a p-value <0.0032 (data not shown).

Changes in metabolites that correlate with LDL-C response to simvastatin. Analysis of the metabolite changes that correlated with LDL-C response in the full range group identified urea cycle intermediates and a group of dibasic amino acids related by shared transporters (Table 2). Specifically, increases in cystine ($p<0.0012$, $q<0.10$), ornithine ($p<0.0068$, $q<0.26$), lysine ($p<0.0100$, $q<0.26$), and citrulline ($p<0.0160$, $q<0.26$) were all observed to correlate with the LDL-C lowering.
effects of simvastatin with significant p-values (<0.05), but high q-values. Individually, these metabolites are not considered statistically significant, but considering the close structural and functional similarities between the first six metabolites correlated to response to simvastatin—we consider this finding compelling from a discovery perspective. Cystine, ornithine, and lysine, the three most significantly correlated metabolites, are all substrates for the cystinuria-related transporter rBAT/B0+AT (SLC3A1/SLC7A9), which mediates uptake of dibasic amino acids at the intestinal and renal membranes. Citrulline and ornithine are also both intermediates in the catabolism of amino acids by the urea cycle and their strong correlation (Figure 2), suggests an increased flux through the urea cycle and amino acid catabolism.

Pre-treatment levels of metabolites correlated with response to simvastatin. We next sought to identify metabolites whose baseline levels were predictive of LDL-C response to simvastatin in the full range group (Table S2). A test of Spearman’s correlation coefficients between post-treatment level of LDL-C and metabolites at baseline adjusting for pre-treatment level of LDL-C showed that greater LDL-C lowering was correlated with lower levels of uridine (p<0.0022, q<0.18) and an increase in shikimic acid (p<0.0096, q<0.38) (Table S3). Shikimate is an indole precursor of phenylalanine, tyrosine and tryptophan, produced by plants and bacteria, but not animals, suggesting increased synthesis by the gut microbiome and/or increased transport of shikimic acid across intestinal membranes. While below the level of statistical significance, we observed increases in fructose and the sugar acids pentonic acid and hexaric acid that correlated with change in LDL-C in the good responder group (data not shown) and were opposite to the effects seen for these metabolites in poor responders (Table 3).

While metabolomics measurements detected no reduction in plasma cholesterol levels in poor responders (an independent verification of clinical measurements) several metabolites did change significantly in the poor responder group upon treatment with simvastatin (Table 3). In poor responders, simvastatin induced a reduction in plasma levels of the sugars fructose (p<0.0012, q<0.039) and glucose (p<0.0020, q<0.039)—the latter strongly correlated with reductions in alpha-mannosylglycerate (0.809, p<0.0001) and pseudouridine (0.704, p<0.0001) (data not shown). Glycolic acid decreased significantly (p<0.0005, q<0.039), and this decrease was correlated in the full range group with a decrease in hydroxylamine (0.598, p<0.002)(not shown). Together, these clusters of metabolites may provide a more robust biomarker for simvastatin non-response than a single changed metabolite.

Analyses in Good and Poor Responders to Simvastatin

Changes in metabolite levels in good and poor responders upon treatment with simvastatin. In good responders we found a decrease in cholesterol (p<0.0022, q<0.18) and an increase in shikimic acid (p<0.0096, q<0.38) (Table S3). Shikiminate is an indole precursor of phenylalanine, tyrosine and tryptophan, produced by plants and bacteria, but not animals, suggesting increased synthesis by the gut microbiome and/or increased transport of shikimic acid across intestinal membranes. While below the level of statistical significance, we observed increases in fructose and the sugar acids pentonic acid and hexaric acid that correlated with change in LDL-C in the good responder group (data not shown) and were opposite to the effects seen for these metabolites in poor responders (Table 3).

While metabolomics measurements detected no reduction in plasma cholesterol levels in poor responders (an independent verification of clinical measurements) several metabolites did change significantly in the poor responder group upon treatment with simvastatin (Table 3). In poor responders, simvastatin induced a reduction in plasma levels of the sugars fructose (p<0.0012, q<0.039) and glucose (p<0.0020, q<0.039)—the latter strongly correlated with reductions in alpha-mannosylglycerate (0.809, p<0.0001) and pseudouridine (0.704, p<0.0001) (data not shown). Glycolic acid decreased significantly (p<0.0005, q<0.039), and this decrease was correlated in the full range group with a decrease in hydroxylamine (0.598, p<0.002)(not shown). Together, these clusters of metabolites may provide a more robust biomarker for simvastatin non-response than a single changed metabolite.

Baseline metabolites that are significantly different between good and poor responders. We detected several metabolites with highly significant correlations between pre-
treatment levels and LDL-C response to simvastatin in the good responder group (Table 4). Lower baseline levels of xanthine (p < 0.0001, q < 0.00066), 2-hydroxyvaleric acid (p < 0.0001, q < 0.0013), succinic acid (p < 0.0009, q < 0.017) and stearic acid (p < 0.0039, q < 0.037) were all significantly correlated with greater LDL-C response. Conversely, higher pretreatment level of galactaric acid (hexaric acid) (p < 0.0034, q < 0.037) was correlated with increased responsiveness to simvastatin.

**Multivariate analysis of metabolomic profiles of good and poor responders at baseline.** Orthogonal partial least square discriminant analysis (OPLS-DA) was used to compare baseline levels of metabolites in good and poor responders (Figure 3). The results shown in Figure 3A are for a three-component model with 2orthogonals that was built on all the good and poor responders. The model yielded a R² of 0.87 and a Q² of 0.31. Furthermore, 7-fold cross validation was then used to better evaluate the prediction of drug response. Specifically, in each round of cross validation, about 6/7 of the subjects were used to build a three component OPLS-DA model, which was then used to predict the drug response for the remaining 1/7 of the subjects. It was found that on average the OPLS-DA models achieved a prediction accuracy of 74% with 70% sensitivity and 79% specificity. The ROC curve of true positive rate vs false positive rate yields an area under the curve (AUC) of 0.84 (Figure 3B). In general, diagnostic testing indicates that modeling of these metabolites yields a robust predictive tool for distinguishing between good and poor responders. Metabolites that contribute to their separation are shown in Figure 3C, with variable importance scores (VIP) and cross validation standard errors (cvSE). Top metabolites that correlate with separation of the groups include xanthine (VIP: 3.5, cvSE: 0.69), 2-hydroxyvaleric acid (VIP: 3.0, cvSE: 0.44), succinic acid (VIP: 2.5, cvSE: 0.78), stearic acid (VIP: 2.3, cvSE: 0.55) and fructose (VIP: 2.0, cvSE: 0.87). Additional metabolites of unknown identity also contributed to the model separating good and poor responders classes (data not shown). This modeling supports the hypothesis that individuals in the tails of the response distribution in the CAP study comprise metabolically distinct subgroups and that their metabolic profiles (metabotypes) might contribute to their differing responses.

**Table 2. Metabolite changes significantly correlated with response to simvastatin treatment in full range participants.**

| Compound    | Association with Response | p-value | q-value |
|-------------|---------------------------|---------|---------|
| cystine     | positive                  | 0.0012  | 0.10    |
| ornithine   | positive                  | 0.0068  | 0.26    |
| lysine      | positive                  | 0.0100  | 0.26    |
| kynurenine  | positive                  | 0.0150  | 0.26    |
| citrulline  | positive                  | 0.0160  | 0.26    |
| glutamine   | positive                  | 0.0270  | 0.37    |

doi:10.1371/journal.pone.0038386.t002

**Discussion**

In this study a mass spectrometry-based metabolomics platform (GC-TOF) that detects small molecules below 550 Da in a broad spectrum of chemical classes and metabolic pathways was used to map global metabolic effects of simvastatin. An untargeted metabolomics approach can yield many unrelated findings; but the dataset reported here has some striking patterns. In broadly sampled full range responders, we have detected an increase in amino acids, specifically essential amino acids and their degradation products. An increase in dibasic amino acids was correlated with response to simvastatin, again not a random set of amino acids, but specifically those transported by the cystinuria and arginine transporters. In poor responders we detected a decrease in plasma fructose, glucose and sugar acids that was not seen in good responders. This combination of findings may suggest a distinct pattern of energy usage between poor responders and the broader spectrum of response phenotypes. Poor responders could also be separated from good responders using an OPLS-DA model of baseline metabolites. Together these findings suggest that metabolomics analysis might be developed for defining a population unlikely to benefit from statin use sufficient to warrant risk of the spectrum of side-effects.

A more detailed analysis of the GC-TOF data reveals changes in a diverse set of compounds, some anticipated and some unexpected. The expected changes included decreased free cholesterol in individuals selected from both the full range of LDL-C response (Table 1) and those selected from the 10% tail of good responders (Table S2), but not from the poor response tail (Table 3). The very strong correlation of cholesterol with alpha and gamma tocopherol (vitamin E) may reflect the close relationship between tocopherols and cholesterol metabolism. In addition to their antioxidant effects, alpha tocopherol modulates LDL receptor concentrations, and reduces CD36 receptor and ABC1 transporter expression [22,23,24,25]. Simvastatin has been shown previously to reduce alpha-tocopherol levels in plasma following both short-term [26] and long-term exposure [27]. In studies where simvastatin treatment was augmented with alphatocopherol, increased lowering of total and LDL cholesterol was observed [28], indicating that lower alpha-tocopherol levels are not mediating the LDL-C reductions. It has been reported that simvastatin treatment increases the capacity of LDL particles to transport lipid soluble antioxidants [27] and oxygenated and hydrocarbon carotenoids [29], suggesting that the statin-induced reductions in total plasma levels of tocopherol which we observed are accompanied by increased tocopherol content of LDL particles, and hence the net result may contribute to greater resistance of these particles to oxidative stress, and hence to reduced atherogenic potential. Additional pleiotropic effects of simvastatin might include an up regulation of triacylglycerol lipase activity (EC # 3.1.1.3, LIPC) [30]. This might explain the increase in plasma levels of glycerol that we detect in our analysis (Table 1).

The increase in creatinine and modulation of several amino acids with simvastatin treatment (Table 1) was associated with strong correlations among those metabolites (Figure 1) suggesting that a common metabolic pathway was affected. We have also observed that levels of shikimic acid, an enterobacteria-derived precursor of aromatic- and indole-containing amino acids, are also altered by statin treatment in the good responders (Table S2).

Pseudouridine, the C-glycoside isomer of the RNA nucleotide uridine, is present in essentially all ribosomal RNAs and seems to be affected by simvastatin. In humans pseudouridine synthase converts uridine to pseudouridine, which is a dead-end metabolite and generally excreted in urine. An increased level of pseudouridine suggests a decrease in the rate of excretion, but together with a reduced level of uridine, a more likely scenario is an increase in the activity of pseudouridine synthase.

The inter-correlated changes in several amino acids and their degradation products and the correlation between changes in these amino acids and LDL-C change (Figure 2) point to possibly important functions of amino acids in simvastatin mechanism of action. Our data indicate a statin-induced change in amino acid
degradation or transport. Our pathway analysis indicates that metabolites that changed in the full range participants in response to simvastatin (Table 1) were enriched for the pathway class amino acid degradation. In the full range participants, metabolites that correlate with LDL-C response to simvastatin (Table 2) included dibasic amino acids that are substrates for the cystinuria-related transporter, potentially indicating changes in transport. In addition, the changes in citrulline and ornithine suggest an increased flux through the urea cycle (Figure 2, Table 2) again pointing to a change in amino acid degradation. Since simvastatin treatment either has no effect or can improve kidney function \[31,32,33\] it is unlikely that the changes in amino acids were due to renal dysfunction.

The previously published identification of amino acid metabolism as a marker of changes in cholesterol metabolism is consistent with the development of peptide biomarkers of cardiovascular disease \[34\]. In addition, amino acids have been identified as predictors of the risk of developing diabetes and possibly contributing to changes in insulin sensitivity \[16,35\].

The metabolite most significantly different between good and poor responders at baseline was the purine metabolite xanthine, which is implicated in oxidative stress cascades (Table 4). Xanthine is the final breakdown product of purine nucleotides and the immediate precursor of uric acid. Xanthine is the substrate of xanthine oxidase, which produces hydrogen peroxide and hence is implicated in mechanisms of oxidative stress. Since free radicals

Figure 2. Correlation matrix illustrating two clusters of compounds correlated with simvastatin response in full range participants. The two clusters were identified in a clustering analysis for the change of all metabolites (results not shown) according to their pairwise correlations using the MMC algorithm \[14\]. Correlations of metabolites to drug response in LDL-C were given in the first row and column, and are rescaled (divided by the largest absolute value of them) to be clearer in the map. The color scheme corresponds to correlation strength as shown by the color bar. Red: Better response, more reduction of the metabolite. Blue: Better response, less reduction or increase of the metabolite. Abbreviations: LDL-C, Low-Density Lipoprotein Cholesterol; NIST, National Institute of Standards and Technology. doi:10.1371/journal.pone.0038386.g002
are known to decouple NOS enzymatic activity, a lower basal level of xanthine and purine degradation may yield an environment for poor responders. Metabolites significantly altered by simvastatin in poor responders.

**Table 3.** Metabolites significantly altered by simvastatin in poor responders.

| Compound                | Direction of Change | p-value  | q-value |
|-------------------------|---------------------|----------|---------|
| glycolic acid           | decrease            | 0.0005   | 0.039   |
| fructose                | decrease            | 0.0012   | 0.039   |
| glucose                 | decrease            | 0.0020   | 0.039   |
| pentonic acid*          | decrease            | 0.0020   | 0.039   |
| ethanolamine            | decrease            | 0.0072   | 0.11    |
| 1-hexadecanol           | decrease            | 0.0130   | 0.16    |
| hydroxylamine           | decrease            | 0.0180   | 0.2     |
| threonic acid           | decrease            | 0.0250   | 0.24    |
| pseudo uridine          | decrease            | 0.0310   | 0.24    |
| pelargonic acid         | decrease            | 0.0340   | 0.24    |
| pentonic acid           | decrease            | 0.0370   | 0.24    |
| succinic acid           | decrease            | 0.0390   | 0.24    |
| hexaric acid*           | decrease            | 0.0420   | 0.24    |
| α-mannosylglycerate     | decrease            | 0.0420   | 0.24    |
| uric acid               | decrease            | 0.0460   | 0.24    |

*indicates a partially identified compound: pentonic acid is an aldonic acid with five carbons and hexaric acid is an aldonic acid with six carbons.

DOI: 10.1371/journal.pone.0038386.t003

Metabolites with baseline levels significantly different between good and poor responders among extreme range participants.

**Table 4.** Metabolites with baseline levels significantly different between good and poor responders among extreme range participants.

| Compound          | Association with Response | p-value  | q-value |
|-------------------|---------------------------|----------|---------|
| xanthine          | negative                  | <0.0001  | 0.0068  |
| 2-hydroxyvaleric acid | negative            | <0.0001  | 0.0013  |
| succinic acid     | negative                  | 0.0009   | 0.017   |
| stearic acid      | negative                  | 0.0032   | 0.037   |
| hexaric acid*     | positive                  | 0.0034   | 0.037   |
| heptadecanoic acid| negative                  | 0.0260   | 0.19    |
| pelargonic acid   | negative                  | 0.0300   | 0.19    |
| 4-hydroxyproline  | negative                  | 0.0300   | 0.19    |
| capric acid       | negative                  | 0.0320   | 0.19    |
| oxoproline        | negative                  | 0.0360   | 0.19    |
| pentonic acid*    | negative                  | 0.0410   | 0.21    |
| fructose          | negative                  | 0.0460   | 0.21    |

*indicates a partially identified compound: pentonic acid is an aldonic acid with five carbons and hexaric acid is an aldonic acid with six carbons.

DOI: 10.1371/journal.pone.0038386.t004

degradation attenuates NO production by inhibiting arginine transport at the NOS associated CAT-1 transporter [39]. It has not escaped our attention that statin effects on arginine transport function may contribute to therapeutic effects on endothelial function by increasing NOS activity.

Recent studies employing *ex vivo* cultures of intestinal bacteria to metabolize simvastatin have revealed a degradation of drug, producing a series of metabolites including and similar to 2-hydroxyvaleric acid [2-hydroxypentanoic acid] [40]. We detected 2-hydroxyvaleric acid as a significantly decreased metabolite following *ex vivo* treatment with simvastatin (Table 1). Since this metabolite is present in simvastatin naive samples and is decreased by simvastatin treatment, it is possible that simvastatin, or a metabolite of simvastatin, inhibits an enzyme that produces 2-hydroxyvaleric acid. Conversely, low basal levels of 2-hydroxyvaleric acid exhibit a highly significant correlation to LDL-C reduction in good and poor responders (Table 4). This suggests lower activity of a promiscuous enzyme that produces 2-hydroxyvaleric acid, and perhaps metabolizes simvastatin, might also result in lower rates of simvastatin degradation and differential pharmacokinetics. This observation, as well as those described for shikimic acid above, suggests that variation in gut microbiome activity can contribute to mechanism of variation in response to simvastatin (Table S2). An influence of gut micoflora on simvastatin response was also suggested by our recent finding that several secondary bile acids derived from microbial metabolism are predictive of LDL-C response to simvastatin in the CAP study [9]. This suggests that genetic, gut microbiome and environmental interactions might all contribute to mechanism of variation of response to simvastatin.

While we consider this study a discovery project to validate the experimental paradigm and elucidate pleiotropic features, the sample size is commensurate with other metabolomics studies. However, larger studies will be necessary to validate clinical utility—which will ideally define pre-treatment metabolic signatures that are predictive of efficacy of simvastatin as well as other statins in reducing clinical cardiovascular events, as well as those that can identify individuals most likely to experience adverse effects of treatment. Further, by assessing such markers, the design of future clinical trials can be improved by excluding individuals who are least likely to derive clinical benefit. The observation that people selected from the ends (best and worst responders) are biochemically distinct suggests that metabolomics might be a powerful tool for sub classification of individuals as an important step in streamlining clinical trials and personalizing treatment. Finally, the application of both mass spectrometry and lipidomics platforms in the CAP study has demonstrated the value of this approach in mapping global metabolic effects of simvastatin and in highlighting the pathways that may modulate variation in its clinical efficacy and in its multiple biological effects. We have undertaken this systems biology approach to define pharmacometabolomic changes to generate hypotheses of pleiotropic mechanisms mediating simvastatin effects. These results suggest that functional studies are warranted into the interaction of simvastatin with endogenous and enterobiotic metabolites at bile and amino acid transporters.

**Materials and Methods**

**Clinical Samples**

Plasma samples were analyzed from participants in the Cholesterol and Pharmacogenetics (CAP) study, a trial in which 944 Caucasian and African-American men and women with total cholesterol levels of 160–400 mg/dL were treated with simvastatin...
at 40 mg per day for six weeks (Table S1). Information about the participants selected for this study has been published previously. Briefly, this study was designed to examine genetic and non-genetic factors affecting the response to simvastatin therapy in healthy, drug-naïve patients [21]. Participants were followed for a total of 6 weeks on simvastatin therapy (40 mg at bedtime) and were seen at clinic visits conducted at two-week intervals. Blood specimens from each participant were obtained after an overnight fast at the screening visit, after a 2-week placebo run-in (enrollment visit), and following 4 and 6 weeks of simvastatin administration. Samples used in this study were collected at baseline and at 6 weeks of therapy. Medication compliance was assessed by pill count every two weeks and averaged over 95%. Overall, treatment with simvastatin lowered low-density lipoprotein (LDL) cholesterol by 54 mg/dl and increased high-density lipoprotein (HDL) cholesterol by 2 mg/dl. The magnitude of the lipid and lipoprotein responses, however, differed among participants according to a number of phenotypic and demographic characteristics [23]. Data on dietary intake was not collected, but subjects were instructed not to change their diet. No minors took part in this study. Approval for this study of the analyses of determinants of simvastatin response in the CAP study was granted by the Children’s Hospital and Research Center Institutional Review Board, University of California San Francisco Committee on Human Research, and University of California Los Angeles Office of the Human Research Protection Program and written informed consent was obtained from all participants. The research was conducted in accordance with the Declaration of Helsinki.

Two subgroups of participants were selected: the first from the extreme range of response, ‘good and poor responders’, consisted of 24 individuals selected from the top 10% of the LDL-C response distribution who were matched for body mass index, race, and gender to 24 individuals in the lowest 10% of responders, with response to therapy defined as the percentage change in LDL cholesterol from baseline. The second set ‘full range’ was 100 individuals randomly selected from the entire CAP study, excluding participants who had been selected for the extreme range group. These full range participants are representative of the population for age, race, gender, and BMI. On the

**Figure 3.** OPLS-DA of baseline metabolites classifies good and poor responders. (A) Orthogonal partial least square discriminant analysis was used to classify good and poor responders based on log-transformed baseline concentration of metabolites ($R^2 = 0.87$, $Q^2 = 0.31$). Good responders are shown in black and poor responders in red. Baseline metabolites were log-transformed and normalized (described in methods). Performance evaluation by 7-fold cross validation yielded the following statistics: prediction accuracy: 74%; sensitivity: 70%; specificity: 79% (not shown). (B) ROC curve of true positive rate (x-axis) versus false positive rate (y-axis) yields an area under the curve (AUC) of 0.84. (C) Baseline metabolites ranked by importance in classifying good and poor responders in the OPLS model. *indicates a partially identified compound: pentonic acid is an aldonic acid with five carbons and hexaric acid is an aldonic acid with six carbons. Abbreviations: VIP, variable importance score; cvSE, standard error derived from cross validation.

doi:10.1371/journal.pone.0038386.g003
other hand, the extreme range subset provides a means to explore the differences in metabolite profiles and predictors of the highest and lowest responses to drug therapy. Metabolomic analyses of statin-induced changes in bile acids in both groups [9] and the major lipid classes in the full range participants have been reported recently [19].

**GC-TOF Mass Spectrometry Analysis**

Plasma samples (30 μl) were extracted and derivatized as reported previously [41]. Briefly, 15 μl aliquots were extracted by 1 ml of degassed acetonitrile/isopropanol:water (3:3:2) at –20°C, centrifuged and decanted with subsequent evaporation of the solvent to complete dryness. A clean-up step with acetonitrile/water (1:1) removed membrane lipids and triglycerides and the supernatant was dried down again. Internal standards C8–C30 fatty acid methyl esters (FAMEs) were added and the sample was derivatized by methoxyamine hydrochloride in pyridine and subsequently by N-methyl-trimethylsilyltrifluoroacetamide (MSTFA) (1 ml bottles, Sigma-Aldrich) for trimethylsilylation of acidic protons.

A Gerstl MPS2 automatic liner exchange system was used to inject 1 μl of sample at 50°C (ramped to 250°C) in splitless mode with 25 s splitless time. An Agilent 6890 gas chromatograph (Santa Clara CA) was used with a 30 m long, 0.25 mm i.d. Rtx5Sil-MS column with 0.25 μm 5% diphenyl film and additional 10 m integrated guard column was used (Restek, Bellefonte PA). Chromatography was performed at constant flow of 1 ml/min ramping the oven temperature from 50°C for to 330°C with 22 min total run time. Mass spectrometry was done by a Leco Pegasus IV time of flight mass spectrometer with 280°C transfer line temperature, electron ionization at –70 V and an ion source temperature of 250°C. Mass spectra were acquired from m/z 65–500 at 20 spectra s⁻¹ and 1750 V detector voltage. Result files were exported to our servers and further processed by our metabolomics BinBase database [42]. All database entries in BinBase [41] were matched against the Fiehn mass spectral library of 1,200 authentic metabolite spectra using retention index and mass spectrum information or the NIST05 commercial library. Identiﬁed metabolites were reported if present with at least 50% of the samples per study design group (as deﬁned in the SetupX database) [43].

**Statistical Analyses**

The Wilcoxon signed rank test was used to evaluate lipid changes in metabolites pre and post treatment. For relationships between changes in metabolite and statin response of LDL-C, metabolite changes were deﬁned as post-treatment level minus pre-treatment level. For the 100 randomly selected full range participants, metabolite changes were correlated with statin response of LDL-C by calculating their Spearman’s correlation coefﬁcients with post-treatment level of LDL-C, adjusting for pre-treatment level of LDL-C. The adjusted Spearman’s correlation is equivalent to the Pearson’s correlation between the residuals of the linear regression of the ranks of post-treatment level of LDL-C and the metabolite change on the ranks of pre-treatment level of LDL-C. To associate metabolite changes with statin response of LDL-C using good and poor responder data, the diﬀerence of metabolite changes between good responders and poor responders using the Wilcoxon rank sum test was tested. Those signiﬁcant metabolites are the compounds whose change is associated with statin response of LDL-C.

For predicting response of LDL-C to simvastatin, baseline metabolite levels were correlated with statin response of LDL-C by calculating their Spearman’s correlation coefﬁcients with post-treatment level of LDL-C, adjusting for pre-treatment level of LDL-C using the same aforementioned method. In order to associate metabolites at baseline to statin response in LDL-C using extreme subjects’ data, the diﬀerence in metabolites at baseline between good responders and poor responders was tested using the Wilcoxon rank sum test. For all the above univariate tests, q-values [44] were calculated for controlling multiple testing false discovery rate.

Correlations among metabolites were obtained by deriving Spearman’s correlation coefficient between each pair of metabolites. Correlation matrices were used to visualize the correlation between metabolites and drug responses. The modulated modularity clustering algorithm is used to cluster metabolites based on their pairwise Spearman’s correlation coefﬁcients [45].

Orthogonal partial least square discriminate analysis (OPLS-DA) was used to classify good and poor responders. OPLS-DA is built on OPLS [46], a modiﬁcation of the widely used PLS method. Compared to PLS, OPLS is able to separate variation in metabolomics data into two parts that are related or unrelated to the drug response phenotype, which facilitates the interpretation of results with preserved prediction ability [46]. The OPLS-DA model was built on log-transformed and then normalized baseline concentration of metabolites. Normalization was performed by subtracting each metabolite by its sample mean and dividing that by its standard error. The software SIMCA-P+ version 12.0 was used to perform the analysis. Two orthogonal components were included in the model. A variable importance (VIP) score is used to rank metabolites’ contribution in separating the two response groups. Prediction diagnostics were derived from 7-fold cross validation. Each fold contains balanced numbers of good and poor responders.

**Supporting Information**

**Table S1** Demographics of CAP patients included in the current GC-TOF metabolomics study. The table lists the comparison of the full-range, good and poor responder subgroups used in this study based on age, gender, race, BMI, change in LDL-C and basal levels of LDL-, HDL- and total cholesterol.

**Table S2** Metabolites for which baseline levels were significantly correlated with response to simvastatin in full range participants. The table shows the association of pre-treatment levels of gluconic acid, pseudouridine, maltose, leucine and uridine to the amount of change in LDL-C after simvastatin administration. Metabolites listed are signiﬁcantly correlated to response to simvastatin based on p-values, but not following correction for false-discovery rate (q-values).

**Table S3** Metabolites signiﬁcantly altered by simvastatin in good responders among extreme range participants. The table shows the direction of change in cholesterol, shikimic acid and ethanolamine following simvastatin administration. Metabolites listed are signiﬁcantly altered by simvastatin based on p-values, but not following correction for false-discovery rate (q-values).
Author Contributions
Conceived and designed the experiments: RKD RMK. Performed the experiments: OF WRW. Analyzed the data: MT HZ RB. Contributed reagents/materials/analysis tools: HZ PDK ZBJ. Wrote the paper: MT RKD.

References
1. Grundy SM, Cleeman JI, Mertz CN, Brewer HB Jr, Clark LT, et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227–239.
2. Jaisinoka M, Owsarecz J, Orszulak-Michalak D (2007) Staining: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 59: 483–499.
3. Rode RM, Peric R, Rolek M, Krauss RM (2008) Pharmacogenomics of statin resistance. Curr Opin Mol Ther 10: 553–561.
4. Vaquerio MP, Sanchez Munie FJ, Jimenez Redondo S, Prats Olivan P, Higueras FJ, et al. (2010) Major diet-drug interactions affecting the kinetic characteristics and hypolipidemic properties of statins. Nutr Hosp 25: 193–206.
5. Rode RM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195–2207.
6. Bai JP (2010) Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics. Drug Metab Pharmacokinet 25: 62–71.
7. Clayton TA, Baker D, Lendon JC, Everett JR, Nicholson JK (2009) Metabolomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A 106: 14728–14733.
8. Kaddurah-Daouk R, Raadie RA, Zhu H, Zeng ZB, Wiest MM, et al. (2010) Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS ONE 5: e25482.
9. 9. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM (2008) Metabolomics: a global biochemical approach to drug discovery and disease. Annu Rev Pharmacol Toxicol 48: 653–683.
10. Kaddurah-Daouk R, Kruhnhan KR (2009) Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 34: 173–186.
11. Han X, Rosen S, Boyle SH, Helegge C, Cheng H, et al. (2011) Metabolomics in early Alzheimer’s disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS ONE 6: e21643.
12. Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, et al. (2010) Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry 15: 938–953.
13. Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, et al. (2010) Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naive patients with schizophrenia. PLoS ONE 5: e9508.
14. Kecskés JS, Wilson ID, Lendon JC (2011) Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics 12: 103–111.
15. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, et al. (2011) Metabolic profiles and the risk of developing diabetes. Nat Med 17: 448–453.
16. Wang Z, Klipfell E, Bennett BJ, Koehler R, Levison BS, et al. (2011) Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472: 65–63.
17. Ji Y, Hebrero S, Zhu H, Jenkins GD, Biermack J, et al. (2011) Glycine and a glycine dehydrogenase (GDH) SNP as an in-vitro/cellular response biomarkers in depression: pharmacometabonomics-informed pharmacogenomics. Clin Pharmacol Ther 89: 97–104.
18. Kaddurah-Daouk R, Raadie RA, Zhu H, Zeng ZB, Wiest MM, et al. (2010) Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study. Metabolomics 6: 191–201.
19. Kaddurah-Daouk R, Boyle SH, Matzen W, Sharma S, Matzen S, et al. (2011) Pretreatment metabolism as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl Psychiatry 1: e26.
20. Simon JA, Fan F, Huley SB, Blanche PJ, Waters D, et al. (2006) Phenotypic predictors of response to simvastatin therapy among African-American and Caucasians: the Cholesterol and Pharmacogenetic (CAP) Study. Am J Cardiol 97: 843–850.
21. Pal S, Thomson AM, Bottema CD, Roach PD (2000) Alpha-tocopherol modulates the low density lipoprotein receptor of human HepG2 cells. J Nutr 130: 5.
22. Rode S, Rubic T, Lorenz RL (2008) Alpha-Tocopherol disturbs macrophage LXRalpha regulation of ABCA1/G1 and cholesterol handling. Biochem Biophys Res Commun 369: 968–972.
23. Devaraj S, Hugou J, Jialal I (2001) Alpha-tocopherol decreases CD36 expression in human monocyte-derived macrophages. J Lipid Res 42: 321–327.
24. Ricciarelli R, Zingg JM, Azzi A (2000) Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle cells. Circulation 102: 82–87.
25. Human JA, Ubbink JB, Jelling J, Delpert R, Vermaak WJ, et al. (1997) The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Clin Chim Acta 263: 67–77.
26. Buskamp T, Abolam Y, Van Laar J, Njoku I, Strandberg T, et al. (2004) Effect of 12-month statin therapy on antioxidant potential of LDL, and serum antioxidant vitamin concentrations. Ann Med 36: 618–622.
27. Neunteufel T, Kostner K, Kateshchacher R, Zehetgruber M, Maurer G, et al. (1998) Additional benefit of vitamin K supplementation to simvastatin therapy on vasoactivity of the brachial artery of hypercholesteremic men. J Am Coll Cardiol 32: 711–716.
28. Ryden M, Leanderson P, Kassbom KO, Jonasson L (2010) Effects of simvastatin on carotenoid status in plasma. Nutr Metab Cardiovasc Dis.
29. Premura-Stolzman M, Premura-Miklacek A, Miklacek Z (2003) Effect of simvastatin on trioleylglycerol hydrolysis and transacylation with cholesterol in serum of outpatients with coronary heart disease. Drug Exp Clin Res 29: 37–43.
30. Baigent C, Landray M, Leiper P, Altmann P, Armitage J, et al. (2005) First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 45: 473–484.
31. Huskey J, Lindenfeld J, Cook T, Targer G, Kendrick J, et al. (2009) Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis 202: 202–206.
32. Namli S, Olhaz H, Turgut F, Alisir T, Tufan T, et al. (2007) Improvement of enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS ONE 5: e1000479.
33. Keshishian H, Addona T, Burgess M, Mani DR, Shi X, et al. (2009) Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry 15: 938–953.
34. Dawson J, Walters M (2006) Uric acid and xanthine oxidase: future therapeutic effects on xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58: 87–114.
35. Dawson J, Walters M (2006) Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol.
36. Schwartz IF, Gruppner A, Chernichowski T, Hillel O, Engel A, et al. (2011) Hyperuricemia attenuates aortic nitric oxide generation, through inhibition of arginine transport, in rats. J Vasc Res 48: 252–260.
37. Scholz M, Fiehn O (2007) SetupX—a public study design database for metabolomic projects. Pac Symp Biocomput: 169–180.
38. Kaddurah-Daouk R, Raadie RA, Zhu H, Zeng ZB, Wiest MM, et al. (2010) Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study. Metabolomics 6: 191–201.
39. Rode RM, Peric R, Rolek M, Krauss RM (2008) Pharmacogenomics of statin resistance. Curr Opin Mol Ther 10: 553–561.
40. Fiehn O, Wohlgemuth O, Kolle A, Franz M, Seubert R, et al. (2001) Amino Acids: Variation in Simvastatin Treatment.